Healthcare - Biotechnology - NASDAQ - US
$ 4.2
-0.474 %
$ 13.5 M
Market Cap
-0.1
P/E
CASH FLOW STATEMENT
-15 K
OPERATING CASH FLOW
-224 K
INVESTING CASH FLOW
9.96 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cingulate Inc.
| Net Income | -23.5 K |
| Depreciation & Amortization | 583 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 813 K |
| Change in Working Capital | 7.1 M |
| Others | -26.1 M |
| Free Cash Flow | -15.3 K |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | 23.5 K | (17.7) | (20.7) | (7.2) | (11.5) |
| Depreciation & Amortization | 0.6 | 0.4 | 0.7 | 0.7 | 0.2 |
| Deferred Income Tax | 4.2 | (0.8) | (16.3) | 0 | 0 |
| Stock Based Compensation | 0.8 | 0.8 | 12.8 | 0 | 0 |
| Other Operating Activities | (27.8) | 0.8 | 16.3 | 2.2 | 48.1 K |
| Change in Working Capital | 7.1 | 0.6 | (3.2) | (0.3) | 1.9 |
| Cash From Operations | (15.0) | (15.9) | (10.4) | (6.8) | (9.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 0 | (0.2) | (0.8) | (0.4) | (1.0) |
| Other Items | (0.2) | 768 | 0 | 17.9 K | 3.8 |
| Cash From Investing Activities | (0.2) | (0.2) | (0.8) | (0.4) | 2.7 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 5.0 | (0.5) | 0.5 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.0 | 0 | 6.7 | 7.5 | 6.1 |
| Cash From Financing Activities | 10.0 | 4.9 | 26.5 | 8.0 | 6.1 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (5.3) | (11.1) | 15.3 | 0.8 | (0.6) |
| FREE CASH FLOW | |||||
| Free Cash Flow | 15.3 K | (16.0) | (11.2) | (7.2) | (10.5) |